Shopping Cart 0
Cart Subtotal
USD 0

Nuo Therapeutics Inc (AURX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind the regenerative capacity of the human body to trigger natural healing. The company's flagship product, Aurix System, is a biodynamic hematogel designed to harness a patient's innate regenerative abilities to manage a wide range of wounds. Aurix is US FDA approved platelet and plasma therapy system for managing a wide range of ulcers and exuding wounds, including leg ulcer, diabetic ulcer, pressure ulcer, and all severities such as full thickness, partial thickness and complex wounds. The company has its facilities in Nashville, Tennessee; and Durham, North Carolina. Nuo Therapeutics is headquartered in Gaithersburg, Maryland, the US.

Nuo Therapeutics Inc (AURX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nuo Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Aldagen Raises Additional USD 0.06 Million In Venture Financing 11

Equity Offering 12

Nuo Therapeutics to Raise up to USD11.6 Million in Public Offering of Shares 12

Nuo Therapeutics Raises USD7.5 Million in First Tranche of Private Placement 13

Nuo Therapeutics Raises USD7.3 million in Public Offering of Shares 14

Nuo Therapeutics Raises USD2 Million in Private Placement of Shares 15

Cytomedix Completes Private Placement Of Shares For USD 5 Million 16

Nuo Therapeutics Raises USD5 Million n Private Placement of Shares and Warrants 17

Cytomedix Announces Private Placement Of Shares For USD 15 Million 18

Cytomedix Completes Private Placement Of Shares For USD 7 Million 19

Cytomedix Files Registration Statement For Public Offering Of Securities For Up To USD 35 Million 20

Debt Offering 21

Cytomedix Raises USD26 Million in Second Tranche of Private Placement Debt Securities Due 2019 21

Cytomedix Completes Private Placement Of Notes For USD 3 Million 22

Acquisition 23

Cytomedix Acquires Developer Of Regenerative Cell Therapies, Aldagen 23

Nuo Therapeutics Inc-Key Competitors 25

Nuo Therapeutics Inc-Key Employees 26

Nuo Therapeutics Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Legal and Regulatory 28

Jul 05, 2017: Nuo Therapeutics Receives Advisory Opinion Waiver for Medicare Part B Co-Payments for Patients in Aurix CED Clinical Studies 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nuo Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Nuo Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aldagen Raises Additional USD 0.06 Million In Venture Financing 11

Nuo Therapeutics to Raise up to USD11.6 Million in Public Offering of Shares 12

Nuo Therapeutics Raises USD7.5 Million in First Tranche of Private Placement 13

Nuo Therapeutics Raises USD7.3 million in Public Offering of Shares 14

Nuo Therapeutics Raises USD2 Million in Private Placement of Shares 15

Cytomedix Completes Private Placement Of Shares For USD 5 Million 16

Nuo Therapeutics Raises USD5 Million n Private Placement of Shares and Warrants 17

Cytomedix Announces Private Placement Of Shares For USD 15 Million 18

Cytomedix Completes Private Placement Of Shares For USD 7 Million 19

Cytomedix Files Registration Statement For Public Offering Of Securities For Up To USD 35 Million 20

Cytomedix Raises USD26 Million in Second Tranche of Private Placement Debt Securities Due 2019 21

Cytomedix Completes Private Placement Of Notes For USD 3 Million 22

Cytomedix Acquires Developer Of Regenerative Cell Therapies, Aldagen 23

Nuo Therapeutics Inc, Key Competitors 25

Nuo Therapeutics Inc, Key Employees 26

Nuo Therapeutics Inc, Other Locations 27

Nuo Therapeutics Inc, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Nuo Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind the regenerative capacity of the human body to trigger natural healing. The company's flagship product, Aurix System, is a biodynamic hematogel designed to harness a patient's innate regenerative abilities to manage a wide range of wounds. Aurix is US FDA approved platelet and plasma therapy system for managing a wide range of ulcers and exuding wounds, including leg ulcer, diabetic ulcer, pressure ulcer, and all severities such as full thickness, partial thickness and complex wounds. The company has its facilities in Nashville, Tennessee; and Durham, North Carolina. Nuo Therapeutics is headquartered in Gaithersburg, Maryland, the US.

Nuo Therapeutics Inc (AURX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nuo Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Aldagen Raises Additional USD 0.06 Million In Venture Financing 11

Equity Offering 12

Nuo Therapeutics to Raise up to USD11.6 Million in Public Offering of Shares 12

Nuo Therapeutics Raises USD7.5 Million in First Tranche of Private Placement 13

Nuo Therapeutics Raises USD7.3 million in Public Offering of Shares 14

Nuo Therapeutics Raises USD2 Million in Private Placement of Shares 15

Cytomedix Completes Private Placement Of Shares For USD 5 Million 16

Nuo Therapeutics Raises USD5 Million n Private Placement of Shares and Warrants 17

Cytomedix Announces Private Placement Of Shares For USD 15 Million 18

Cytomedix Completes Private Placement Of Shares For USD 7 Million 19

Cytomedix Files Registration Statement For Public Offering Of Securities For Up To USD 35 Million 20

Debt Offering 21

Cytomedix Raises USD26 Million in Second Tranche of Private Placement Debt Securities Due 2019 21

Cytomedix Completes Private Placement Of Notes For USD 3 Million 22

Acquisition 23

Cytomedix Acquires Developer Of Regenerative Cell Therapies, Aldagen 23

Nuo Therapeutics Inc-Key Competitors 25

Nuo Therapeutics Inc-Key Employees 26

Nuo Therapeutics Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Legal and Regulatory 28

Jul 05, 2017: Nuo Therapeutics Receives Advisory Opinion Waiver for Medicare Part B Co-Payments for Patients in Aurix CED Clinical Studies 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Nuo Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Nuo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Nuo Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 9

Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aldagen Raises Additional USD 0.06 Million In Venture Financing 11

Nuo Therapeutics to Raise up to USD11.6 Million in Public Offering of Shares 12

Nuo Therapeutics Raises USD7.5 Million in First Tranche of Private Placement 13

Nuo Therapeutics Raises USD7.3 million in Public Offering of Shares 14

Nuo Therapeutics Raises USD2 Million in Private Placement of Shares 15

Cytomedix Completes Private Placement Of Shares For USD 5 Million 16

Nuo Therapeutics Raises USD5 Million n Private Placement of Shares and Warrants 17

Cytomedix Announces Private Placement Of Shares For USD 15 Million 18

Cytomedix Completes Private Placement Of Shares For USD 7 Million 19

Cytomedix Files Registration Statement For Public Offering Of Securities For Up To USD 35 Million 20

Cytomedix Raises USD26 Million in Second Tranche of Private Placement Debt Securities Due 2019 21

Cytomedix Completes Private Placement Of Notes For USD 3 Million 22

Cytomedix Acquires Developer Of Regenerative Cell Therapies, Aldagen 23

Nuo Therapeutics Inc, Key Competitors 25

Nuo Therapeutics Inc, Key Employees 26

Nuo Therapeutics Inc, Other Locations 27

Nuo Therapeutics Inc, Subsidiaries 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Nuo Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.